HCN Essentials: AML Induction Therapies | Breast Cancer Prevention | Neuroblastoma Classification System UpdatedAugust 09, 2021 | Oncology Hematology Multisite 11-Year Experience of Less-Intensive vs. Intensive Therapies in Acute Myeloid Leukemia Key Points: In two study cohorts, less-intensive therapies increased mortality in each of three risk groups defined by age, comorbidities, and cytogenetics. The differences became nonsignificant after accounting for physician perception of cure, emphasizing the need for a randomized trial.Design: Multicenter retrospective cohort (1,292), 6 institutions, 2008-2012; prospective cohort (695), 13 institutions, 2013 – 2017Connected Content: Fitness for Intensive Chemotherapy: A Continuing Conundrum Read full article Internal Medicine Breast Cancer Prevention: Time for Change In this comprehensive Journal of Clinical Oncology clinical review, the authors suggest that reexamination of breast cancer risk reduction strategies and clinical practice is needed. Prediction models, breast cancer mortality, prognostic categories, and the Women’s Health Initiative (WHI) randomized trials, dietary modification (DM) trial, hormone therapy trials, estrogen, and estrogen plus progestin trials are all discussed in great detail. Read full article Internal Medicine Revised Neuroblastoma Risk Classification System: A Report from the Children’s Oncology Group It was time for a change in neuroblastoma treatment planning, and this Original Report from the Journal of Clinical Oncology validates a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) while incorporating segmental chromosome aberrations (SCA) as an additional genomic biomarker. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS